Bill Abernethy

Bill Abernethy has extensive work experience in the pharmaceutical industry. Bill is currently working as a Consultant to the CEO and CMO at Silence Therapeutics plc, where they focus on strategic product development. Bill has also held the position of Vice President, Global Market Development at the same company from 2019 to 2021. Prior to that, they served as Senior Vice President Operations at CureDuchenne in 2018, Vice President and General Manager at Marathon Pharmaceuticals, LLC in 2016-2017, and Executive Director, Global Market Development, Neuromuscular Franchise at BioMarin Pharmaceutical Inc. from 2015 to 2016. From 2011 to 2015, Bill Abernethy worked as Vice President, Global Market Development at Prosensa Therapeutics. Bill also has experience at Genzyme, where they held various roles including Senior Director and Director of Global Marketing and Strategic Planning, as well as Director, General Manager of Gaucher Disease. Their career began at Solvay Pharmaceuticals in 1989, where they worked as a Senior Clinical Research Associate and later transitioned into Product Management.

Bill Abernethy attended Auburn University from 1975 to 1981 and obtained a Bachelor of Science degree in Plant Biology. Bill later pursued further education at Mercer University's Stetson School of Business and Economics from 1991 to 1994, where they earned a Master of Business Administration (MBA) degree with a concentration in Marketing.